×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Clinical: DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulat
clinical
3,187 words
KG: DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD
Contents
DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (15)
Selective APOE4 Degradation via Proteolysis Targeting Chimer
Score: 0.79
APOE4 Allosteric Rescue via Small Molecule Chaperones
Score: 0.76
APOE Isoform Conversion Therapy
Score: 0.72
Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides
Score: 0.72
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
Competitive APOE4 Domain Stabilization Peptides
Score: 0.78
Targeted APOE4-to-APOE3 Base Editing Therapy
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE Isoform Expression Across Glial Subtypes
Score: 0.74
APOE4-Selective Lipid Nanoemulsion Therapy
Score: 0.74
Interfacial Lipid Mimetics to Disrupt Domain Interaction
Score: 0.72
Lysosomal Calcium Channel Modulation Therapy
Score: 0.70
FOXO3-Longevity Pathway Epigenetic Reprogramming
Score: 0.63
Blood-Brain Barrier SPM Shuttle System
Score: 0.53
Vocal Cord Neuroplasticity Stimulation
Score: 0.52
Related Analyses (16)
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · completed
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · completed
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · completed
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Show 11 more
Related Experiments (14)
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Levodopa-Induced Dyskinesias Mechanism — Experiment Design
validation · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
iPSC-NPC effects on astrocytes in vitro ICH model
exploratory · completed · Score: 0.90
tACS Connectivity Trial in Early Alzheimer's
clinical · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
Sex Differences in Alzheimer's Disease — mechanisms and ther
clinical · proposed · Score: 0.40
AD Amyloid-Resilient Phenotype Study — Why Some amyloid-Posi
clinical · proposed · Score: 0.40
AD Combination Therapy Trial: Anti-Aβ + Anti-Tau
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Multi-omics analysis of myricanol effects on gene expression
exploratory · proposed · Score: 0.88
Neural Stem Cell Therapy for Alzheimer's Disease
clinical · proposed · Score: 0.40
Show 9 more
See Also (15)
Lecanemab CLARITY-AD Trial
clinical · Pages share 4 hypotheses
TRAILRUNNER-ALZ 1: Remternetug for Early Alzheimer's Di
clinical · Pages share 4 hypotheses
al002-trem2-agonist-alzheimers
clinical_trial · Pages share 4 hypotheses
Donanemab TRAILBLAZER-ALZ 2 Trial
clinical · Pages share 4 hypotheses
LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for
clinical · Pages share 4 hypotheses
LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy
clinical · Pages share 4 hypotheses
APOE4 Homozygous Astrocytes
cell · Pages share 4 hypotheses
Adipose-Derived Mesenchymal Stem Cell Therapy for Early
clinical · Pages share 4 hypotheses
BEACoN Study - Biomarker Exploration in Aging, Cognitio
clinical · Pages share 4 hypotheses
CORT108297 Phase 2 (NCT04601038) - Stress Attenuation i
clinical · Pages share 4 hypotheses
NCT07477431 - Levetiracetam for Persons at Risk for Alz
clinical · Pages share 4 hypotheses
MK-1167 Phase 2 AD Trial (MK-1167-008)
clinical · Pages share 4 hypotheses
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-
clinical · Pages share 4 hypotheses
A Phase IIB, Randomized, Double-Blind, Placebo-Controll
clinical · Pages share 4 hypotheses
nct05508789
clinical_trial · Pages share 4 hypotheses
Show 10 more
Knowledge Graph (3 edges)
DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD
references
APOE
DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD
references
GFAP
DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for AD
references
BDNF
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.